An exploratory placebo controlled, dose ranging study of the effects of TRx0014 [methylthioninium chloride] 30mg tid, 60mg tid and 100mg tid in patients with mild to moderate dementia of the Alzheimer type

Trial Profile

An exploratory placebo controlled, dose ranging study of the effects of TRx0014 [methylthioninium chloride] 30mg tid, 60mg tid and 100mg tid in patients with mild to moderate dementia of the Alzheimer type

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Aug 2015

At a glance

  • Drugs Methylthioninium chloride-TauRx (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors TauRx Therapeutics
  • Most Recent Events

    • 31 Jul 2008 SPECT imaging results were published in the proceedings of the 12th International Conference on Alzheimer's Disease and Related Disorders.
    • 31 Jul 2008 Positron emission tomography results were published in the proceedings of the 12th International Conference on Alzheimer's Disease and Related Disorders.
    • 31 Jul 2008 Results were presented at the 12th International Conference on Alzheimer's Disease and Related Disorders.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top